ADMEDUS LTD (AHZ)

name changed to Anteris Technologies Ltd

we understand that on or about this date the company consolidated its shares 1 for 100

The suspension of trading in the securities of Admedus Limited will be lifted immediately, following the release by AHZ of an announcement a recapitalisation plan.

Admedus has sold the distribution rights to its CardioCel and VascuCel product range for $A36.2 million (including all earnouts) to LeMaitre Vascular Inc. $A22.8M upfront payment plus two instalments of $A1m each after 12 months and 36 months. Up to $A11.4M on earn-out payments for a total $A36.2M (at the current $US0.67/$A1 rate), subject to achievement of certain milestones. Up to 3-year manufacturing contract with 20% margin above cost to AHZ . Retain entire IP portfolio for ADAPT enabling continuation of product development pipeline. Transitions Admedus to focus on advancing its Transcatheter Aortic Valve Replacement programme and other potential products. The transaction is non-dilutive, underpinned by manufacturing revenues and reduced operating expenses and headcount .

The company expects the suspension to last until the earlier of the commencement of normal trading on 15 October 2019, or the release of an announcement by the company in relation to the broader recapitalisation plan.

The company has received regulatory approval for the sale of the CardioCel 3D product portfolio in Israel. The approval allows the company to service a greater segment of the market with a solution for the repair of high-complexity congenital heart defects.

The company expects the suspension of its securities to last until the earlier of the commencement of normal trading on 30 September 2019 or the release of an announcement in relation to the broader recapitalisation plan.

The company lodges its Appendix 4D and Half Yearly Financial Report.

The company has not paid their annual listing fees in respect of the year ending 30 June 2020 but the securities are already suspended from official quotation.

The company issues a response to ASX Appendix 4C Query.

The company has received notice from acromed ag of its intention to terminate the distribution agreement with Admedus for the supply of acromed branded products in Australia and New Zealand.

The company requests a further extension to the voluntary suspension of the quotation of its ordinary securities. The voluntary suspension is necessary for the company to finalise the next phase of the recapitalisation plan which has progressed but has not yet been finalised. The suspension is expected to to last until the earlier of the commencement of normal trading on 2 September 2019, or the release of an announcement.

The company lodges its Appendix 4C - quarterly.

The company requests for an extension to the voluntary suspension of its securities to finalise the next phase of its recapitalisation plan. The suspension is expected to last until the earlier of the commencement of normal trading on 5 August 2019, or the release of an announcement.

The company announces the publication of an independent study assession the performance of CardioCcel in the prestigious peer-reviewed journal, The Annals of Thoracic Surgery.

The company requests a further extension to the voluntary suspension of its securities to finalise the next phase of its recapitalisation plan. The suspension is expected to last until the earlier of the commencement of normal trading on 1 July 2019, or the release of an announcement in relation to the recapitalisation plan.

BTC health completes acquisition of hospital infusion business for $6.3 million.

Admedus confirms completion of the sale of part of its Infusion business to BTC Speciality Health Pty Ltd, a wholly owned subsidiary of BTC Health Limited for A$6.3 million.

The company requests a further extension to the voluntary suspension of the quotation of its ordinary shares. The suspension is expected to last until the earlier of the commencement of normal trading on 4 June 2019, or the release of an announcement by the company in relation to its broader recapitalisation plan.

The company releases the results of its 2019 Annual General Meeting.

The company releases its 2019 AGM Presentation.

BTC Health releases an announcement. BTC health takes decisive step to become a leading supplier of innovative medical products. Acquisition of exclusive rights to ambIT range of infusion pumps for Australia and New Zealand. Forecast annual revenues of $7 million p.a. and growing at 14% p.a. Purchase price of $6.3 million which includes $1.75 million of working capital. Establishes a platform for anticipated strong growth and new product introductions commencing 2H2019.

The company has entered into an agreement to sell part of its Infusion business to BTC Speciality Health, a wholly owned subsidiary of BTC Health Lmited, for $6.3 million. This will complete the first phase of the Infusion business divestiture. Completion of the sale is subject to certain conditions being satisfied with the sale expected to complete in late May 2019.

The company has entered into a facility agreement with SIO Partners for a secured debt facility of A$1 million. The proceeds will provide funds for general working capital and operational costs. The company will continue with the restructure of the business operations to reduce certain overhead costs, and a proposed divestment of the infusion business so as to capitalise on its growing ADAPT business.

The company requests a further extension to the voluntary suspension of its securities to finalise the next phase of its recapitalisation plan. The suspension is expected to last until the earlier of the commencement of trading on 21 May 2019 or the release of an announcement.

The company lodges its Appendix 4C - quarterly.

The company requests a further extension to the voluntary suspension of its securities until the earlier of the commencement of trading on 7 May 2019 or the release of an announcement regarding the next phase of the recapitalisation plan.

The share sale agremeent entered into by its wholly owned subsidiary, Admedus Investments with Constellation Therapeutics and the other sharheolders of Admedus Vaccines for the sale of all of the shares of Admedus Vaccines has been terminated. The Admedus Vaccines board of directors has appointed Peter Anthony Lucas of P A Lucas & Co Pty Ltd as voluntary administrator of Admedus Vaccines. AHZ gives notice that Resolution 6 included in the notice of AGM is withdrawn and will not be considered by shareholders at the AGM.

The company issues a response to ASX Aware Query.

The securities of Admedus Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHZ, pending the release of an announcement regarding the Immunotherapies Transaction.

The suspension of trading in the securities of Admedus Ltd will be lifted immediately, following the release by AHZ of an announcement regarding a capital raising.

The company issues a prospectus for a pro rata renounceable partially underwritten entitlement offer of 5 New Shares for every 7 Existing Shares held at an issue price of $0.08 per New Share to raise up to $20.2 million. Each New Share includes one free attaching New Option with an exercise price of $0.08 that expires three years from the date of issue. The Entitlement Offer is partially underwritten for $9.1 million and commitments have been received from existing Shareholders for a further $4 million. Up to a further $6.3 million in underwriting will be provided if Admedus Limited does not raise a minimum amount under the Entitlement Offer.

Admedus announces a pro rata renounceable partially underwritten entitlement offer to raise up to $20.2 million before costs. Based on underwriting and commitments received by Admedus, the Entitlement Offer is expected to raise a minimum cash amount of $12 million after the payment of underwriter fees and repayment of a $5 million loan to major shareholder Star Bright. Offer of 5 new fully paid ordinary shares for each 7 shares currently held with an attaching option for each new shares issued. The offer price of $0.08 per New Share represents a discount of: 40.74% to the last traded price of shares on ASX on 1 August 2018 of $0.135; and 38.6% to the volume weighted average issue price paid by Star Bright Holding Ltd under the recent placement completed on 5 September 2018 of $0.112. Attaching options will be listed with an 8 cent exercise price and three year exercise period.

The company lodges its Appendix 4C - quarterly.

The company expects the suspension to last until the release of an announcement in relation to the broader recapitalisation plan.

The company lodges its Appendix 4D and Half Yearly Financial Report.

Cornerstone strategic investor secured, raising up to $7.7 million. $5 million unsecured loan facility was entered into with Star Bright, repaying Partners For Growth facility. Company restructure and recapitalisation plan in development.

The company expects that the suspension of its securities will last until the earlier of the commencement of normal trading on 3 September 2018, or the release of an announcement by the company in respect of the company's capital raising as well as a broader recapitalisation of the company.

The compan requests a further extension to the voluntary suspension of its securities. This is expected to last until the earlier of the commencement of normal trading on 20 August 2018, or the release of an announcement by the Company.

The company has renewed its exclusive distribution agreement with Utah-based Summit Medical Products Inc. (Summit) for a further eight years. Under the terms of the extended agreement, Admedus remains the exclusive distributor of Summit's ambIT infusion products in Australia and New Zealand until 2026.

The company expects the suspension of its securities to last until the earlier of the commencement of normal trading on 13 August 2018, or the release of an announcement regarding a capital raising.

The securities of Admedus Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of the Company, pending the release of an announcement regarding a Placement with potential investors in respect of the capital raising.

we understand that on or about this date the company consolidated its shares 1 for 10

name changed from Allied Healthcare Group Ltd